2. Nymox Pharmaceutical (NYMX)
Company Profile: Nymox Pharmaceutical is a biopharmaceutical company engaged in the research and development of diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer's disease.
Altman Z-score: -114.08Closing Price: $3.72 (Sept. 15) Financial Metrics: Nymox Pharmaceutical has a negative book value, as liabilities outpace assets. Nymox's quick ratio, which measures the ability to meet short-term obligations with its most liquid assets, is 0.5, indicating the company would be unable to meet its current liabilities. Analyst Consensus: No research firm has coverage of Nymox Pharmaceutical.